A BSTRACT Introduction: Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition characterized by the presence of intrusive thoughts, referred to as obsessions, and repetitive behaviors, known as compulsions. Globally, OCD affects approximately 2–3% of the population. Materials and Methods: Three databases (PubMed, Web of Science, and MEDLINE) were explored for the present study, from January 1, 2000 to December 31, 2024. The analysis was conducted using R version 4.3.2 to estimate the overall treatment effect of memantine and risperidone for OCD, relative to placebo, via meta-analysis. The Pooled Standardized Mean Differences (SMDs) were computed using both fixed-effect and random-effects models. Results: Only 10 studies were included in current investigation, after identification of 2362 articles. Meta-analysis of memantine suggested statistically insignificant ( P value = 0.06) reduction in Y-BOCS score [SMD: –1.02 (–2.12, 0.08)], whereas meta-analysis of risperidone suggested statistically significant ( P value = 0.03) reduction in Y-BOCS score [SMD: –0.38 (–0.74, –0.02)]. Conclusion: Risperidone plays a significant role in reduction of Y-BOCS score in OCD patients, whereas memantine does not show a significant effect in reducing the Y-BOCS score in OCD patients.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: